EEG
GNMX

E.E. Geduld’s Aevi Genomic Medicine Inc GNMX Stock Holding History

E.E. Geduld’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-32,500
Closed -$262K – 323
2015
Q1 		$262K Buy
+32,500
New +$245K 0.17% 132

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

E.E. Geduld's GNMX Position: Q2 2015 in Review

E.E. Geduld sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2015, closing a stake of 32,500 shares — an estimated $262K sold.

E.E. Geduld first reported a position in GNMX in Q1 2015 and held it in 1 quarter. The position peaked at $262K in Q1 2015. 54 funds tracked by Wall St. Rank hold GNMX as of Q2 2015.

  • E.E. Geduld reported no remaining Aevi Genomic Medicine Inc position as of Q2 2015 after selling out during the quarter.
  • E.E. Geduld sold 32,500 Aevi Genomic Medicine Inc shares in Q2 2015, an estimated $262K.
  • E.E. Geduld first reported a position in Aevi Genomic Medicine Inc in Q1 2015 and held it in 1 quarter.
  • E.E. Geduld's Aevi Genomic Medicine Inc position peaked at $262K in Q1 2015.
  • 54 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2015.

Based on E.E. Geduld's 13F filing for Q2 2015, filed 7 Aug 2015.